Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Keedy on Regorafenib for the Treatment of GIST

November 12th 2013

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Promising TH-302 Results Accelerate Sarcoma Study

September 25th 2013

The list of agents currently available to treat soft-tissue sarcoma is rather short, with no drugs being approved on the basis of an improvement in overall survival in approximately 20 years.

Combination of Cixutumumab and Temsirolimus Demonstrates Improved Progression-Free and Encouraging Overall Survival for Bone and Soft Tissue Sarcoma

August 29th 2013

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.

Dr. Van Tine on Identifying Biomarkers in Sarcomas

August 12th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Dr. Van Tine on Arginine Deiminase for Sarcomas

June 11th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.

Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma

May 29th 2013

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

Imatinib Therapy Matures: GIST Research Sheds Light on Mutations, Drug Levels

March 26th 2013

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Palifosfamide Trial Reaches Target for PFS Events

February 12th 2013

The phase III PICASSO 3 trial examining palifosfamide plus doxorubicin in metastatic soft tissue sarcoma has reached its goal for progression-free survival events.

Surgery Following Imatinib Boosts Survival for GIST Patients

January 23rd 2013

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

ï»¿Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment

November 19th 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups

October 3rd 2012

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

No Survival Advantage for Ifosfamide Added to Doxorubicin in Advanced Soft Tissue Sarcoma

October 2nd 2012

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Dr. Demetri Describes the MOA of Regorafenib in GIST

September 10th 2012

Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.

Dr. Demetri Explains the Side Effects of Regorafenib

June 20th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.

Pazopanib Receives FDA Approval for Treatment of Soft Tissue Sarcoma

April 27th 2012

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.

Immunotherapy and Radiation Provide Good Tumor Response in Sarcoma Patients

April 16th 2012

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.

ODAC Recommends Pazopanib But Not Ridaforolimus for Sarcoma

March 21st 2012

ODAC has recommended the approval of pazopanib but ruled against the agent ridaforolimus to treat sarcoma.

Pazopanib Shows 3-Fold Improvement in Progression-Free Survival

August 4th 2011

Patients with anthracycline-treated sarcomas had a 3-fold improvement in PFS with antiangiogenic agent pazopanib versus placebo.